Skip to content
value.today
PMV Pharmaceuticals, Inc. logo

PMV Pharmaceuticals, Inc.

PMVP
$113 Mmarket cap on Oct 9, 2026-25.5% since Jan 2024
Compare
World rank
#18,312
Revenue
—
For year ending December-2025
Net income
$-78 M
SEC filing
Employees
35
As on 2021
value.today research

PMV Pharmaceuticals, Inc. in brief

PMV Pharmaceuticals, Inc. is a listed company in the Biotechnology industry, based in California, USA. Its market value was $113 M on 9 October 2026, which makes it the 18,312th largest listed company in the world and the 3,465th largest in the USA on this site. It employs about 35 people and David Henry Mack is its chief executive. Its shares trade under the symbol PMVP (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About PMV Pharmaceuticals, Inc.

PMV Pharmaceuticals is a management team of Biopharmaceutical experts with extensive experience in oncology drug discovery and development company. The company annual net income is 4.9 million USD. The headquarters is in USA.

PMV Pharmaceuticals, Inc. timeline

2 events, 2017–2020
  1. 2017
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2020
  4. 🔔
    Initial public offering on Nasdaq
    Final prospectus filed with the SEC on 25 September 2020; shares registered for exchange trading on 21 September 2020.

Events of PMV Pharmaceuticals, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$744 M$1.5 B$2.2 B$3.0 B202120222023202420252026

World rank over time

▼ down 13,869 places since 2021
2021-01-01: #4514#4,51420212022-01-07: #10376#10,37620222022-12-25: #13900#13,90020222023-07-30: #15655#15,65520232024-01-05: #19395#19,39520242026-03-08: #10169#10,16920262026-08-01: #18598#18,59820262026-10-09: #18383#18,3832026

Rank in USA: #1,431 (Jan 2021) · #2,697 (Jan 2022) · #2,855 (Dec 2022) · #3,175 (Jul 2023) · #3,443 (Jan 2024) · #1,972 (Mar 2026) · #3,626 (Aug 2026) · #3,437 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
1.1×
Free cash flow yield
-65.4%
Net margin
—
Operating margin
—
Return on equity
-74.2%
Liabilities / assets
10.2%
Profit per employee
$-2.2 M

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue —, net income $-18M—FY18Fiscal year ending Dec 2019: revenue —, net income $-25M—FY19Fiscal year ending Dec 2020: revenue —, net income $-34M—FY20Fiscal year ending Dec 2021: revenue —, net income $-58M—FY21Fiscal year ending Dec 2022: revenue —, net income $-73M—FY22Fiscal year ending Dec 2023: revenue —, net income $-69M—FY23Fiscal year ending Dec 2024: revenue —, net income $-59M—FY24Fiscal year ending Dec 2025: revenue —, net income $-78M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-86M$-78M—
Dec 2024——$-85M$-59M—
Dec 2023——$-80M$-69M—
Dec 2022——$-77M$-73M—
Dec 2021——$-58M$-58M—
Dec 2020——$-35M$-34M—
Dec 2019——$-27M$-25M—
Dec 2018——$-19M$-18M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-74M$0M$-74M$-1.48—
Dec 2024$-51M$1M$-52M$-1.14—
Dec 2023$-56M$1M$-57M$-1.44—
Dec 2022$-64M$8M$-72M$-1.61—
Dec 2021$-47M$1M$-48M$-1.28—
Dec 2020$-33M$0M$-33M$-2.40—
Dec 2019$-22M$0M$-22M$-8.35—
Dec 2018$-15M$0M$-16M$-5.82—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-23M—Dec ’24Three months to Mar 2025: revenue —, net income $-17M—Mar ’25Three months to Jun 2025: revenue —, net income $-21M—Jun ’25Three months to Sep 2025: revenue —, net income $-21M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-18M—Dec ’25Three months to Mar 2026: revenue —, net income $-18M—Mar ’26Three months to Jun 2026: revenue —, net income $-18M—Jun ’26Three months to Sep 2026: revenue —, net income $-34M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-34M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of PMV Pharmaceuticals, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-86 M
Net income
$-78 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$117 M
Total liabilities
$12 M
Total equity
$105 M

As of December-2025

Top 65 institutional investors in PMV Pharmaceuticals, Inc.#

As of Sep 30, 2026
65 institutions held 56.5 M shares (about 74.8% of the shares outstanding) on Sep 30, 2026. The ten largest hold 54.2%. Source: SEC Form 13F filings, filed through Nov 16, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in PMV Pharmaceuticals, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1BML Capital Management, LLC7,330,000+2,000,000 (+37.52%)9.70%$12 MNov 6, 2026
2Tang Capital Management LLC7,285,085+3,040,000 (+71.61%)9.64%$12 MNov 16, 2026
3Samsara Biocapital, LLC7,240,000New9.59%$12 MNov 16, 2026
4Sio Capital Management, LLC3,634,137+1,000,000 (+37.96%)4.81%$6 MNov 16, 2026
5Vanguard Capital Management LLC3,083,667+1,071,647 (+53.26%)4.08%$5 MNov 13, 2026
6ADAR1 Capital Management, LLC2,700,349+2,499,341 (+1243.40%)3.58%$5 MNov 16, 2026
7Euclidean Capital LLC2,627,6430 (0.00%)3.48%$4 MNov 16, 2026
8Two Sigma Investments, LP2,429,330+475,194 (+24.32%)3.22%$4 MNov 16, 2026
9Adage Capital Partners GP, L.L.C.2,360,0000 (0.00%)3.12%$4 MNov 16, 2026
10Acadian Asset Management LLC2,285,479+69,585 (+3.14%)3.03%$4 MNov 9, 2026
11Boxer Capital Management, LLC2,050,000New2.71%$3 MNov 16, 2026
12Eversept Partners, LP1,964,624+73,720 (+3.90%)2.60%$3 MNov 16, 2026
13Affinity Asset Advisors, LLC1,750,000New2.32%$3 MNov 13, 2026
14ArrowMark Colorado Holdings LLC1,694,798-264,781 (-13.51%)2.24%$3 MNov 16, 2026
15Millennium Management LLC1,461,926New1.94%$2 MNov 16, 2026
16BlackRock, Inc.916,518-3,300 (-0.36%)1.21%$2 MNov 13, 2026
17BIT Capital GmbH714,407+306,852 (+75.29%)0.95%$1 MNov 13, 2026
18Geode Capital Management, LLC500,327+27,169 (+5.74%)0.66%$1 MNov 6, 2026
19Aldebaran Capital, LLC489,540+22,108 (+4.73%)0.65%$1 MNov 13, 2026
20Walleye Capital LLC487,141+151,447 (+45.11%)0.64%$1 MNov 13, 2026
21Bridgeway Capital Management, LLC427,528-1,325 (-0.31%)0.57%$1 MNov 16, 2026
22Assenagon Asset Management S.A.328,744-331,262 (-50.19%)0.44%$1 MOct 15, 2026
23Vanguard Fiduciary Trust Co301,866+47,091 (+18.48%)0.40%$1 MNov 13, 2026
24Citadel Advisors LLC268,338+221,030 (+467.21%)0.36%$0 MNov 16, 2026
25Bank Of America Corp /de/265,898+25,788 (+10.74%)0.35%$0 MNov 16, 2026
Show all 65: investors 26 to 65
Institutional investors 26 to 65 in PMV Pharmaceuticals, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Marshall Wace, LLP220,760-100,850 (-31.36%)0.29%$0 MNov 13, 2026
27State Street Corp183,1780 (0.00%)0.24%$0 MNov 12, 2026
28RBF Capital, LLC162,2000 (0.00%)0.21%$0 MNov 13, 2026
29Goldman Sachs Group Inc156,869+19,875 (+14.51%)0.21%$0 MNov 16, 2026
30MAI Capital Management133,1220 (0.00%)0.18%$0 MNov 12, 2026
31Susquehanna International Group, LLP130,673+93,142 (+248.17%)0.17%$0 MNov 16, 2026
32Connor, Clark & Lunn Investment Management Ltd.110,086+77,626 (+239.14%)0.15%$0 MNov 10, 2026
33HRT Financial LP103,270+52,760 (+104.45%)0.14%$0 MNov 13, 2026
34Rangeley Capital, LLC99,2400 (0.00%)0.13%$0 MNov 16, 2026
35Northern Trust Corp93,0470 (0.00%)0.12%$0 MNov 16, 2026
36Ikarian Capital, LLC89,1360 (0.00%)0.12%$0 MNov 16, 2026
37Empowered Funds, LLC75,575New0.10%$0 MNov 13, 2026
38Accurate Wealth Management, LLC50,0000 (0.00%)0.07%$0 MOct 20, 2026
39Jacobs Levy Equity Management, Inc35,817-34,687 (-49.20%)0.05%$0 MNov 16, 2026
40HSBC Holdings PLC30,8910 (0.00%)0.04%$0 MNov 16, 2026
41Barclays PLC27,536-225 (-0.81%)0.04%$0 MNov 6, 2026
42Gsa Capital Partners LLP27,382New0.04%$0 MNov 16, 2026
43Boothbay Fund Management, LLC27,1260 (0.00%)0.04%$0 MNov 16, 2026
44Quadrature Capital Ltd23,756-38,314 (-61.73%)0.03%$0 MNov 13, 2026
45Vanguard Global Advisers, LLC21,5590 (0.00%)0.03%$0 MNov 13, 2026
46Point72 Asset Management, L.P.18,819New0.02%$0 MNov 16, 2026
47Pathstone Holdings, LLC17,4870 (0.00%)0.02%$0 MNov 13, 2026
48Corient Private Wealth LP15,0000 (0.00%)0.02%$0 MNov 16, 2026
49Jane Street Group, LLC14,245-25,962 (-64.57%)0.02%$0 MNov 12, 2026
50Morgan Stanley13,719-27,965 (-67.09%)0.02%$0 MNov 13, 2026
51Sand Hill Global Advisors, LLC12,5390 (0.00%)0.02%$0 MNov 13, 2026
52Independent Advisor Alliance12,5000 (0.00%)0.02%$0 MNov 10, 2026
53Claret Asset Management Corp10,703New0.01%$0 MNov 16, 2026
54Deerfield Management Company, L.P.8,7900 (0.00%)0.01%$0 MNov 16, 2026
55Silver Grove Financial Group, Inc.5,0820 (0.00%)0.01%$0 MNov 5, 2026
56PNC Financial Services Group, Inc.2,205-65,733 (-96.75%)0.00%$0 MNov 6, 2026
57Russell Investments Group, Ltd.2,001New0.00%$0 MNov 6, 2026
58Jones Financial Companies Lllp1,0000 (0.00%)0.00%$0 MNov 13, 2026
59Tower Research Capital LLC (TRC)1,000-64 (-6.02%)0.00%$0 MNov 16, 2026
60Jpmorgan Chase & Co614+400 (+186.92%)0.00%$0 MNov 12, 2026
61BNP Paribas Financial Markets5180 (0.00%)0.00%$0 MNov 12, 2026
62Caitong International Asset Management Co., Ltd375+357 (+1983.33%)0.00%$0 MOct 29, 2026
63UBS Group AG3610 (0.00%)0.00%$0 MNov 10, 2026
64Group One Trading LLC155+65 (+72.22%)0.00%$0 MNov 10, 2026
65Royal Bank Of Canada77+1 (+1.32%)0.00%$0 MNov 16, 2026

Mutual funds holding PMV Pharmaceuticals, Inc.#

22 funds hold shares worth $5 M (about 5.2% of the company). Since their previous reports 6 added shares and 10 sold.
Mutual funds holding PMV Pharmaceuticals, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.1.49 M$2 M2.0%<0.01%no changeJun 30, 2026
🇺🇸 Meridian Small Cap Growth FundArrowMark Colorado Holdings, LLC1.06 M$1 M1.4%0.52%−2.1%Jun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.452,363$1 M0.60%<0.01%−0.4%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC232,874$0 M0.31%<0.01%+5.0%May 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors160,526$0 M0.21%0.01%+40%Jun 30, 2026
🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC76,900$0 M0.10%0.07%no changeJun 30, 2026
🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P.74,050$0 M0.10%<0.01%−0.4%Jun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC71,190$0 M0.09%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC59,924$0 M0.08%<0.01%no changeMay 31, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.45,045$0 M0.06%<0.01%newJun 30, 2026
🇺🇸 Tiff Multi-Asset FundTIFF Advisory Services, LLC41,912$0 M0.06%<0.01%−15%Jun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC43,138$0 M0.06%<0.01%+258%May 31, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.27,547$0 M0.04%<0.01%−18%Jun 30, 2026
🇺🇸 NVIT Small Cap Value FundNATIONWIDE FUND ADVISORS14,496$0 M0.02%<0.01%−68%Jun 30, 2026
🇺🇸 Diversified Equity Alpha Master PortfolioBlackRock Fund Advisors13,167$0 M0.02%<0.01%−18%Jun 30, 2026
🇺🇸 Multi-Manager Small Cap Equity Strategies FundColumbia Funds Series Trust I13,237$0 M0.02%<0.01%no changeMay 31, 2026
🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC11,700$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC10,722$0 M0.01%<0.01%+23%Jun 30, 2026
🇺🇸 NVIT Multi-Manager Small Company FundNATIONWIDE FUND ADVISORS7,891$0 M0.01%<0.01%−67%Jun 30, 2026
🇺🇸 Avantis Total Equity Markets ETFAmerican Century ETF Trust4,716$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 LVIP Dimensional U.S. Core Equity 1 FundLincoln Financial Investments Corporation356$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC295$0 M<0.01%<0.01%+6.1%Jul 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 22 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at PMV Pharmaceuticals, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
26
since
-$1.5 M$0Nov 2023: bought $0 (0 trades), sold $196 K (1 trades)Nov 23Sep 2024: bought $0 (0 trades), sold $15 K (2 trades)SepJul 2025: bought $0 (0 trades), sold $151 K (4 trades)JulSep 2025: bought $0 (0 trades), sold $900 K (1 trades)SepOct 2025: bought $0 (0 trades), sold $1.5 M (1 trades)Oct
Bought (open market)Sold (open market)Hover a month for the totals
PMV Pharmaceuticals, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed David Henry MackPresident and CEO, DirectorOption exercise+220,643$1.370$302 K451,109Form 4
filed OrbiMed Capital GP V LLC10% ownerSellindirect-1.00 M$1.520$1.5 M4.98 MForm 4
filed Orbimed Advisors LLC10% ownerSellindirect-500,000$1.800$900 K5.98 MForm 4
filed Michael CarulliChief Financial OfficerSell-28,249$1.060$30 K60,146Form 4
filed Deepika JalotaChief Development OfficerSell-33,065$1.060$35 K89,959Form 4
filed David Henry MackPresident and CEO, DirectorSell-58,411$1.060$62 K536,133Form 4
filed Robert TicktinGeneral Counsel & COOSell-23,151$1.060$25 K98,695Form 4
filed David Henry MackPresident and CEO, DirectorOption exercise+17,709$0.530$9 K551,919Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: PMV Pharmaceuticals, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
2.2 M
4.0% of shares · 5.62 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 5.265-for-1 split

Fails to deliver

  • : 623 shares at $1.49
  • : 4,474 shares at $1.31
  • : 1,839 shares at $1.26
  • : 1 shares at $1.15
  • : 2,933 shares at $1.44

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

PMV Pharmaceuticals, Inc. scorecard#

Passes 3 of the 12 checks that could be worked out: strongest in valuation (1 of 4), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 9, 2026.

  • Valuation1 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median1.1×Price to book 1.1× against Biotechnology's median of 2.9×.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • ✗Free cash flow yield above 5%-65.4%Free cash flow is -65.4% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-1.48 vs -1.14Diluted EPS -1.48 in fiscal 2025 against -1.14 the year before (report's currency).
    • ✗Net income higher than five years earlier-$78 M-$78 M in fiscal 2025 against -$34 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$78 MNet income -$78 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-55.4%-55.4% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 2
    • ✓Short-term assets cover short-term liabilities10.1×Current ratio 10.09 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns1 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✓Share count up no more than 2% in a year1.9%Diluted shares up 1.9% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

PMV Pharmaceuticals, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

PMV Pharmaceuticals, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018
Income statement
Research and development7059565236242114
General and administrative1627242522115.95.0
Operating expenses8685807758352719
Operating income−86−85−80−77−58−35−27−19
Net interest income6.311113.60.40.71.31.3
Other non-operating income (expense)6.311113.70.50.51.31.4
Income before tax−80−75−69−73−58−34−25−18
Income tax−2.2−160.0−0.00.00.00.00.0
Net income including minority interests−78−59−69−73−58−34−25−18
Net income attributable to shareholders−78−59−69−73−58−34−25−18
Earnings per share, basic-1.48-1.14-1.44-1.61-1.28-2.40-8.35-5.82
Earnings per share, diluted-1.48-1.14-1.44-1.61-1.28-2.40-8.35-5.82
Shares, weighted average (basic)535248464514——
Shares, weighted average (diluted)5352484645143.03.0
Balance sheet
Cash and cash equivalents38413810817236173—
Short-term investments75129165133125—28—
Other current assets2.36.23.55.13.33.30.6—
Current assets115176207247301365102—
Property, plant and equipment0.20.411113.10.60.7—
Right-of-use (leased) assets0.81.18.49.510———
Total assets117191252270332366103—
Accounts payable3.26.63.23.03.21.62.8—
Current liabilities11141411126.44.5—
Lease liabilities (non-current)0.40.8121311———
Total liabilities12152624236.44.6—
Retained earnings−446−369−310−241−168−110−75—
Shareholders' equity105176226246309359−70−46
Total liabilities and equity117191252270332366103—
Shares outstanding5352514645453.0—
Cash-flow statement
Share-based compensation5.98.912105.31.90.91.1
Cash from operating activities−74−51−56−64−47−33−22−15
Capital expenditure−0.0−0.7−1.0−8.0−1.3−0.1−0.1−0.5
Cash from investing activities7053−51−1.4−144283.222
Shares issued——35——223——
Cash from financing activities0.50.3361.02.029362—
Change in cash−2.92.3−71−64−188288436.5
Report10-K10-K10-K10-K10-K10-K10-K10-K

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Executive pay at PMV Pharmaceuticals, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$1.7 M
David H. Mack, Ph.D.
Other top executives, average
$898 K
the CEO earned 1.9× this
$100 invested is now
$14
PMV Pharmaceuticals, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025David H. Mack, Ph.D.$1.7 M$958 K$898 K$14
2024David H. Mack, Ph.D.$4.8 M$2.2 M$1.7 M$7
2023David H. Mack, Ph.D.$2.2 M$514 K$1.2 M$13

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at PMV Pharmaceuticals, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Restructuring 1 · Directors and officers 2 · Material agreement 1 · Agreement ended 1 · Shareholder vote 3 · Results announced 13

PMV Pharmaceuticals, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Directors and officers8-K
Material agreement8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Results announced8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Results announced8-K
Agreement endedResults announced8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Restructuring8-K
Directors and officers8-K
Results announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026

Acquisitions and funding#

1 private funding rounds before listing

Private share sales · funding history

Private share sales of PMV Pharmaceuticals, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Feb 2017$74 MNo. 1$50 to $250 million9equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

H-1B hiring at PMV Pharmaceuticals, Inc.#

1 labor condition applications certified in fiscal 2026 for 1 positions, at a median wage of $145 K a year.

Certified, FY2026
1
#1,846 among companies on value.today
Worker positions
1
Median wage offered
$145 K
a year, full-time
Applications filed
1
PMV Pharmaceuticals, Inc.: most frequent H-1B job titles in fiscal 2026
Job titlePositionsMedian wage offered
Senior Pharmacokinetic ScientistMedical Scientists, Except Epidemiologists1$145 K

Where: Princeton, NJ 1

PMV Pharmaceuticals, Inc.: labor condition applications by fiscal year
Fiscal yearCertifiedPositionsMedian wageFiled
FY202611$145 K1
FY202422$68 K2
FY202322$68 K2

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as PMV Pharmaceuticals

Layoffs at PMV Pharmaceuticals, Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
0
2024–2024
Latest
—
2024-01-18
PMV Pharmaceuticals, Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2024············—
PMV Pharmaceuticals, Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
30% of workforceRestructuring planSEC 8-K“(the “ Company ”) announced a restructuring plan involving the reduction of its workforce by approximately 30% of the Company’s employees.”Filing

Source: State WARN notices and SEC 8-K item 2.05

How PMV Pharmaceuticals, Inc. compares in Biotechnology

  • Market cap$113 M · higher than 38% of 726
  • Price / book1.1× · lower than 78% of 534
  • FCF yield-65.4% · higher than 19% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
PMV Pharmaceuticals, Inc.🇺🇸$113 M———
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 9, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As on 2021
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at PMV Pharmaceuticals, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show PMV Pharmaceuticals, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about PMV Pharmaceuticals, Inc.? Suggest a correction